General Psychiatry - Articles - Page 60

A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

July 3, 2019

Talia Puzantian, Chris Aiken, MD, and Chris Aiken

Talia Puzantian, PharmD, BCPP Chris Aiken, MD. Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Solriamfetol (Sunosi) was just approved for excessive daytime sleepiness in narcolepsy and sleep apnea, but it may have important psychiatric effects as well.

Brexanolone (Zulresso) for Postpartum Depression

July 3, 2019

Talia Puzantian, Chris Aiken, MD, and Chris Aiken

Talia Puzantian, PharmD, BCPP Chris Aiken, MD Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.

RESEARCH UPDATE

A New Proposal for SSRI Withdrawal

July 3, 2019

Greg Sazima, MD and Chris Aiken, MD

Drs. Sazima and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The way we taper serotonergic antidepressants may need to be rethought, and this study suggests a new method.

SSRI withdrawal symptoms

July 3, 2019

Use this PDF tool to check if the patient is having any SSRI withdrawal symptoms at baseline.

Mood Stabilizers and Stroke Risk in Bipolar Disorder

July 3, 2019

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity

Why does stroke matter in bipolar disorder? Because it’s the leading cause of death for these patients. Some mood stabilizers raise the stroke risk, while others do not.

New Augmentation Strategies in OCD

July 3, 2019

Michael Posternak, MD.

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Two medications show promise in OCD, and their mechanisms are novel: one glutamatergic, one dopaminergic.

Lithium in Geriatric Depression

July 3, 2019

Jason Mallo, DO

Jason Mallo, DO Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Lithium is underutilized in geriatric depression, but this study suggests it may have unique benefits there.

CME Post-Test - Side Effects Part I, TCPR, June/July 2019

July 3, 2019

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.

Learning Objectives, Side Effects Part I, TCPR, June/July 2019

July 1, 2019

After reading these articles, you should be able to…

Talking to Parents About Prescribing Stimulants

May 26, 2019

Because they work better than anything else to help kids focus, stimulant medications are standard treatments for ADHD. But when you suggest prescribing these medications, typically parents have questions and concerns, says Caroline Fisher, PhD, MD, Chief of Child Psychiatry at Samaritan Health Systems in Corvallis, OR.In an article she...

General Psychiatry
RSS

A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

Brexanolone (Zulresso) for Postpartum Depression

A New Proposal for SSRI Withdrawal

SSRI withdrawal symptoms

Mood Stabilizers and Stroke Risk in Bipolar Disorder

New Augmentation Strategies in OCD

Lithium in Geriatric Depression

CME Post-Test - Side Effects Part I, TCPR, June/July 2019

Learning Objectives, Side Effects Part I, TCPR, June/July 2019

Talking to Parents About Prescribing Stimulants

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

A Scam for Every Woman, Child, and Man: Part 2

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry
RSS